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Research
AbstrACt
Objectives To illuminate patterns observed in 
International Cancer Benchmarking Programme studies 
by extending understanding of the various influences on 
presentation and referral with cancer symptoms.
Design Cross-country comparison of Denmark, England 
and Sweden with qualitative analysis of in-depth interview 
accounts of the prediagnostic process in lung or bowel 
cancer.
Participants 155 women and men, aged between 35 
and 86 years old, diagnosed with lung or bowel cancer in 
6 months before interview.
setting Participants recruited through primary and 
secondary care, social media and word of mouth. 
Interviews collected by social scientists or nurse 
researchers during 2015, mainly in participants’ homes.
results Participants reported difficulties in interpreting 
diffuse bodily sensations and symptoms and deciding 
when to consult. There were examples of swift referrals 
by primary care professionals in all three countries. In all 
countries, participants described difficulty deciding if and 
when to consult, highlighting concerns about access to 
general practitioner appointments and overstretched primary 
care services, although this appears less prominent in the 
Swedish data. It was not unusual for there to be more than 
one consultation before referral and we noted two distinct 
patterns of repeated consultation: (1) situations where the 
participant left the primary care consultation with a plan 
of action about what should happen next; (2) participants 
were unclear about under which conditions to return to the 
doctors. This second pattern sometimes extended over many 
weeks during which patients described uncertainty, and 
sometimes frustration, about if and when they should return 
and whether there were any other feasible investigations. 
The latter pattern appeared more evident in the interviews in 
England and Denmark than Sweden.
Conclusion We suggest that if clear action plans, as 
part of safety netting, were routinely used in primary care 
consultations then uncertainty, false reassurance and the 




No single factor is likely to explain why differ-
ences in cancer outcomes persist between 
high-income countries with universal health 
coverage. The International Cancer Bench-
marking Partnership (ICBP), which compares 
cancer registry data and cross-country surveys, 
has explored several hypotheses about why 
variations occur. These studies have shown a 
number of potentially modifiable factors, for 
example, that patterns in public knowledge 
about cancer awareness and beliefs were not 
clearly associated with variations in survival 
across countries.1 The ICBP studies have 
also drawn attention to different patterns in 
public willingness to consult a Primary Care 
professional (PCP), with patients in the UK 
reporting particular concern ‘not to waste the 
strengths and limitations of this study
 ► This study provides a social science informed, 
qualitative cross-country comparison of 155 in-
depth interviews with bowel and patients with lung 
cancer recruited within 6 months of a diagnosis in 
Sweden, Denmark and England.
 ► The methods we use provide insight into why and 
how potentially modifiable factors identified by 
the International Cancer Benchmarking Project—
including response to symptom experiences, 
differences in willingness to consult, how people 
negotiate access to healthcare and what happens 
during consultations—affect the time to diagnosis 
in a primary care setting.
 ► The study was limited to patient interviews and no 
‘first-hand’ observational data were available to 
compare accounts.
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doctor’s time’.1 There are also cross-country differences 
in general practitioners (GPs) who expressed willingness 
to refer a patient with suspicious symptoms at their first 
presentation, and PCPs have reported that investigations 
such as CT and MRI were harder to access, and results 
took longer in England and Denmark than in Sweden.2 
There seems to be a relationship between smoking 
behaviour and willingness to consult: in separate, recent 
studies, both English3 and Danish smokers4 have been 
shown to be less likely than non-smokers to consult with 
red flag lung cancer symptoms. It has been suggested that 
this is related to the shame, blame and stigma associated 
with lung cancer as a smoking-related disease.5 Socio-
economic deprivation, inequalities in service provision 
and regional differences in expectations about the likely 
consequences of seeking care further contribute to a 
complicated picture.
Denmark, England and Sweden (all ICBP participants) 
were selected for this comparison because survival for lung 
and bowel cancer between 1995 and 2007 were persistently 
higher in Sweden than in Denmark or England, particu-
larly in the first year after diagnosis.6 We chose lung and 
bowel cancer because they affect both genders, are the 
two most common causes of death from cancer across 
Europe,7 their symptomatology is often diffuse or vague 
and they are often prone to late-stage diagnosis. Earlier 
diagnosis has become a key healthcare research and 
policy target in all three countries.8–10 Analyses of poten-
tially modifiable factors have drawn attention to between-
country differences in stage at diagnosis and access to good 
care, diagnostics and screening.11 Late presentation and 
long diagnostic intervals are also potentially modifiable 
contributory factors to poor survival.6 11–15 Cross-country 
comparative research can suggest routes for service rede-
sign as well as hypotheses for further research.16 Social 
and health sciences have suggested potentially modifi-
able factors affecting the time to diagnosis include public 
response to symptom experiences,1 3–5 17–26 differences 
in willingness to consult,1 3–5 17–24 how people negotiate 
access to healthcare,1 18 22 27 28 what happens during 
consultations2 27 29–31 and access to diagnostic tests.2 While 
surveys and cancer registry data can provide excellent 
high-level comparative data showing patterns of associa-
tion, in-depth qualitative research is needed to help illu-
minate why and how observed variations may occur.32 33 
We therefore designed a study to contribute a qualitative 
cross-country comparative analysis of narrative inter-
views with patients recently diagnosed with lung or bowel 
cancer in Denmark, England and Sweden. In this paper, 
the research question we ask is, what might explain some 
of the variations identified in the ICBP?
the healthcare systems in Denmark, England and sweden
All three countries have primarily tax-based health systems. 
However, in Sweden, patient copayments vary from no 
payment to Kr300 per primary care visit, depending on 
county council, up to a total of ~Kr1100 (£100) per year.34 
No copayments are made in England and Denmark, 
although there are prescription charges in all three coun-
tries. In Sweden two-thirds of GPs are publicly employed, 
whereas in Denmark and England most are self-em-
ployed.34 Sweden spends over 20% more on healthcare 
per head of population than England.35 Contact with 
primary care varies between the three countries: Swedish 
patients consult PCPs least frequently (2.9 per annum) 
followed by Denmark (4.7 per annum) and UK (5.0 per 
annum, which includes telephone consultations).36 In 
2015, England withdrew guidance stipulating access for 
urgent appointments within 48 hours.34 In some settings 
in Sweden, a nurse is the first person a patient speaks to 
when seeking an appointment.34 Most first contact in 
Denmark and England is with a receptionist, who may 
pass the patient to a nurse to be triaged. In Denmark, 
some receptionists have been trained to recognise poten-
tially serious symptoms.34 GPs have a central role in 
making referrals to lung and colorectal specialists in all 
three countries34 The national cancer plan in Sweden is 
regionally administered and focused on secondary care,37 
whereas in England and Denmark, specific clinical guid-
ance and targets for PCPs are also included.34 England 
(implemented 2006) and Denmark (implemented 
2014) have national cancer screening programmes for 
bowel cancer. In Sweden, bowel screening was imple-
mented regionally, with some regions having some form 
of programme from 2008. Currently, it is recommended 
for those aged 60–74 years, although this again varies 
by region. Denmark has increased rapid access clinics 
and access to investigations, while in England, referral 
management systems have been interspersed between the 
GP and secondary care.34 38
MEthODs
sampling and recruitment
We interviewed 155 people during 2015 who were 
within 6 months of a diagnosis of lung or bowel cancer 
in the three countries. Purposive sampling39 within 
each country was used to achieve gender balance and 
variation across age, urban and rural locations and 
pathway to diagnosis (see table 1). An experienced 
sociologist in England (JM) and an anthropologist 
in Denmark (TON) recruited and conducted all the 
interviews in their countries, while three experienced 
nurse researchers collaborated in different regions of 
Sweden (BMB, SH and MM). Participants were initially 
approached by treating clinicians in hospital clinics in 
all three countries. To reach data saturation, in England 
and Denmark, this approach was supplemented with 
some additional recruitment from support groups, 
social media and word of mouth. All potential partic-
ipants were provided with an information sheet that 
included the rationale for the study and an explanation 
of what would be involved if they consented to take part 
in the study. Data saturation40 was judged to have been 
reached in the analytical categories for all three coun-
tries before recruitment closed.
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Data collection
Interviews took place in participants’ homes, unless they 
preferred another location. One-to-one interviews were 
preferred, but a small number of participants requested 
a non-participating family member to be present. Inter-
views started with an open-ended question: ‘Could you 
start by telling me, in your own words and in as much 
detail as you want, about everything that has happened 
since you first started to suspect there might be a problem 
with your health?’ Interviews lasted between 45 min and 
1.5 hours. During the interview, the researchers used a 
semistructured topic guide based on social science theo-
ries and the cancer research literature (highlighted in the 
Introduction), including factors related to the diagnostic 
interval.1–5 17–31 The research team had extensive discus-
sions about the topics to ensure comparable data were 
collected.41 Interviews were audio recorded and tran-
scribed verbatim.
Analysis
Monthly teleconferences with the field research team 
(all of whom had a high level of spoken and written 
English) were held throughout the development of the 
topic guide, recruitment, data collection and analysis 
phases. Interview accounts were analysed for narrative 
themes that structured participant experiences. To do 
this, in each country, interview transcripts were imported 
into specialist computer software (NVivo V.10) for organ-
ising textual data and were coded by the interviewing 
researchers. The three research teams conducted separate 
thematic analysis with their own data using a coding frame 
developed through discussion in the teleconferences and 
based on the (anticipated) themes from the topic guide 
and on emergent themes.42 One 2-day and one 4-day anal-
yses and writing workshops were held with the research 
teams from all three countries. Anticipated issues drew 
on existing knowledge and theoretical insights.1–5 17–31 
Emerging analyses were iteratively tested within and 
between datasets. Allocations between the analysis cate-
gories (including identifying participants who described 
leaving the PCP consultation with an understanding of 
what should happen next and those who reported uncer-
tainty about what to do) was discussed among the field 
researchers. Direct quotes from the interviews (translated 
into English by the bilingual researchers) are used to 
illustrate the results. Analysis and findings are presented 
in accordance with relevant Consolidated Criteria for 
Reporting Qualitative Research43 criteria for reporting 
qualitative data and are consistent with interpretive 
approaches to analysis.44
Patient involvement
Public and Patient Involvement (PPI) was conducted in 
accordance with good practice in each country. Repre-
sentatives in England with experience of bowel or lung 
cancer were involved in preparing the funding appli-
cation, the study design and the multidisciplinary advi-
sory group, as well as advising on recruitment strategies, 
including the patient information sheets. In all three 
countries, PPI members were invited to comment on the 
draft interview topic guide. A group of three English PPI 
members met with the research team to look at a subset of 
the English data. Drafts of study papers have been circu-
lated to the advisory panel. Summaries of the main study 
findings, prepared for a stakeholder final event in 2017, 
will be circulated to all study participants who expressed 
interest in seeing the results.
results
We compared the three sets of interviews to consider the 
following potentially modifiable steps, drawn from the 
literature, on the prediagnosis pathway: people’s initial 
responses to bodily sensations and the transformation of 
these into symptoms justifying medical advice; accounts 
of accessing medical help; what happened in the consul-
tation and planning for follow-up.
Awareness and responses to signs and symptoms
The first potentially modifiable factors are the type of 
sensations and bodily changes people considered to justify 
seeking help. Participants in all three countries described 
considerable uncertainty about the possible implications 
of bodily sensations and when or if they should be consid-
ered symptoms warranting medical advice, especially if 
they felt well. For example, apart from some blood in 
his stools, a participant in England said he had been ‘fit 
as anything and not feeling ill at all’ (England—BC18). 
Even those who looked up their symptoms and risk factors 
online were reassured if they found that relatively few 
items on the checklists applied to them. People reasoned 
Table 1 Participant demographic characteristics across the three countries.
Denmark England Sweden Percentages
BC LC BC LC BC LC BC LC
Number of participants 28 22 25 20 30 30 54% 46%
Female 13 8 12 10 14 15 47% 46%
Age range 31–50 2 0 4 2 2 2 10% 5%
51–70 19 15 13 12 14 21 55% 67%
71–90 7 7 8 6 14 7 35% 28%
BC, bowel cancer; LC, lung cancer.
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that they must be low risk if they felt they had a good 
diet, were physically active, non-smokers (or long-term 
ex-smokers), generally fit, relatively young or without a 
family history of cancer. This reasoning suggested that 
some patients expected there to be a linear relationship 
between healthy input and outcomes. For example, a 
participant in Denmark who acknowledged “[I] smoke 
and [drink] alcohol and [eat] too much meat…” went on 
to suggest that other behaviours offered some protection 
from the profile of a typical cancer :
Denmark—BC01: I have read about this, I’m very 
much into organic food. All the things you say can 
cause cancer… you don’t know […]. I have at least 
lived a healthy life with vegetables everyday…and 
fruit, so maybe I’m not the typical cancer patient.
Persistent coughs, pains, stomach aches, changes in 
bowel habits, bleeding or constipation were attributed 
to everyday causes or to more familiar diseases such 
as influenza, pneumonia, irritable bowel syndrome 
(IBS) or haemorrhoids.21 People with lung cancer, who 
smoked cigarettes, reasoned that a persistent cough was 
a ‘normal’ bodily response to smoking. Thus, even those 
who are aware that they have risk factors, or suspicious 
symptoms, may conclude that overall their risk is low 
and not seek medical help. Consistent with Zola’s classic 
work on triggers to the consultation, when people did 
consult this was usually because the symptoms, inter-
fered with daily life, became evident to others who 
encouraged them to consult or exceeded a self-imposed 
time limit22 rather than they suspected that they might 
have cancer.
Access to primary care
The second potentially modifiable factor is whether the 
participant felt able to access primary care. There were 
some apparent differences in accounts from the three 
countries. In England, people talked about long waiting 
times for ‘non-urgent’ appointments or (echoing ICBP 
findings) said they were reluctant to trouble busy GPs with 
potentially minor illnesses that might be treatable with 
over-the-counter remedies.1 A participant in England, 
later diagnosed with bowel cancer, had concluded, ‘It’s 
haemorrhoids, leave it. Doctors are busy with other things’ 
(England—BC20). Another participant in England with 
lung cancer explained why she had not consulted with a 
cough:
England—LC12: When you hear that the GPs are 
so busy and being bothered by, you know, minor 
illnesses it makes you reluctant to go with something 
that you think [is minor] . . . I was, well, “What can 
the doctor do? They won’t want to give you antibiotics 
for a virus.” That was what I, I thought. And I just 
didn’t want to really bother the doctor.
A participant in Denmark similarly reflected on an 
implication of GPs’ time pressures:
Denmark—LC15: The system is not always that easy. 
First you have to convince the secretary, that you 
need an appointment, right. That is what happens 
when they are too busy.
In contrast, we were struck that accounts in Sweden 
rarely included detailed justifications for using the 
doctor’s time nor did they suggest that the onus was on 
the participant to determine whether the matter was 
serious or urgent. For example, a participant in Sweden 
diagnosed with bowel cancer said:
Sweden—BC051: It began like this, that I found a 
little blood I can say in the stool, very little . . . And 
I tend to ignore such things but this was just strange 
enough, so I thought, “no, I’ve got to go to the health 
centre and hear what it is”. And so I did.
Another participant in Sweden with lung cancer said, 
“It’s better to go one time too many than one too few” 
(Sweden-LC102). This sentiment was not expressed in 
any of our interviews in England.
During the consultation
The third potentially modifiable factor is what happens 
when the patient presents with symptoms. Seeking 
healthcare is not just a matter of making an appointment, 
but also of being able to present one’s problem and be 
heard.9 In all three countries, there were examples of a 
single consultation and a prompt referral. A participant 
in England said:
England—BC18: Our local GP was brilliant, she said, 
“I’m not gonna do the kind of normal give you this 
stool sample packet, all that kinda stuff. I’m gonna 
hotline you straight to [hospital] down the road there 
for an endoscopy. Skip all the intermediate stuff and 
go straight into endoscopy,” which was a fabulous 
decision, if you think of it.
Similarly a participant in Denmark explained,
Denmark—BC13: The stomach pains had been 
going on for a while, but 1 day I just could not stand 
it anymore and drove straight down to my doctor’s 
office. My doctor examined it and immediately said: 
“I will send you off to the hospital.” And I was [sent 
off] in the afternoon. That was quick.
A participant in Sweden with bowel cancer recalled the 
GP saying, “No, I cannot see anything, but for safety’s sake 
I will send you to a specialist […] so they get a closer look 
at it.” (Sweden—BC051)
There were also examples of participants in all three 
countries who told us that they had returned to the 
doctors over periods of weeks or even months before 
they were referred for further investigations. Some 
participants in England and Denmark diagnosed with 
lung cancer said they had been repeatedly treated with 
antibiotics for chest infections. Participants diagnosed 
with bowel cancer from all three countries described 
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inconclusive consultations for presumed constipation, 
haemorrhoids, IBS, Crohn’s or psychological causes; 
however, in our data, this appeared more often in inter-
views from Denmark and England. This example from 
England typifies this:
England—BC09: . . . each time it was treated 
obviously as constipation. There was never even any 
mention of anything else. He’s [the GP] a very, “I 
can do it. I can fix it. I can do it.” But each time I 
come away, it was so sort of disheartening, because 
it seemed to be about what he could do and not 
actually helping the situation. But I did have, I had 
all sorts of laxatives from him. It’s as if like we just 
keep trying to do this, but I was in agony each time 
I took it. I did explain that each time. . . But, yeah, 
nothing really. It was more like the repetitive sort of 
appointment.
Making plans for follow-up
The fourth potentially modifiable factor is what happens 
after those consultations which do not include a referral. 
We looked in detail at the accounts of those participants 
who reported two or more presentations before referral 
and noted two different types of experience, depending 
on whether or not the patient reported leaving the consul-
tation knowing what to do next.
Repeated consultation(s) with patient awareness of next steps
First, there were participants in all three countries who 
described leaving the consultation with an understanding 
about what to expect, including how long to wait for 
symptoms to abate, what should prompt them to return 
and what would happen after that. For example, this 
participant in Sweden said:
Sweden—LC129: And then the [GP] said, “No it’s 
nothing. Your lungs sound very healthy, but you’ve 
had this cough for the last 8 weeks and if it does not 
disappear in another week, then please call us. Then 
we’ll see.”
The participants in this ‘planned’ group had also known 
what would be likely to happen if and when they did 
return; all three countries included examples of people 
who knew that further treatments or investigations would 
be needed if the symptoms did not resolve:
England—LC17: And he [GP] prescribed 2 weeks 
antibiotics. And then he said that after that, if it 
didn’t make any difference then he might prescribe 
omeprazole and maybe then a chest x-ray.
Follow-up advice can be reinforced by practice staff 
when delivering a normal test result in the course of their 
diagnostic investigations.45 For example, a participant 
in Sweden reported that the practice nurse said, “if [it] 
gets worse—for example if you lose weight—contact us 
directly” (Sweden-BC055).
Repeat consultation(s) with patient uncertainty about next steps
Second, there were participants who were unsure what 
would or should happen next, such as England—BC09 
quoted above who described a ‘disheartening’ and ‘repeti-
tive sort of appointment’. These participants included those 
who worried that it was not appropriate to return to the 
doctor with the same symptoms and those who had been 
reassured at the initial consultation. The following partici-
pant in Denmark had requested a colonoscopy after many 
months of unusual symptoms and several investigations for 
other possible causes.
Denmark—BC05: I can see now that I had these 
symptoms for 3 years. They [the doctors] thought 
that it was only the myalgia. But it probably was the 
colon cancer, even though I did not have the usual 
symptoms, you know. No bleeding, or diarrhoea or 
constipation. Just this strange heaviness in my lower 
parts. So I had an ultrasound of my bladder and 
kidneys, an x-ray of my lumbar area… And then I 
finally asked for a colonoscopy. My doctor asked me 
if I was sure… of course I was… but I had not thought 
of cancer.
In these accounts people had been unsure what to 
expect and left without a plan about what to do next. 
Unsurprisingly, people who had presented on two, three 
or more occasions described some frustration. In retro-
spect, some wondered if the PCP had decided that a ‘test 
of time’ or ‘wait-and-see’ was the best course of action, 
without sharing their reasoning.30 31
England—BC03: And the simple thing and I agree 
the most obvious thing was, you know, piles and 
irritable bowel syndrome . . . I guess they, the thought 
was, “Well we’ll send her away with that for now and if 
doesn’t work, she’s bound to come back.”
Accounts of repeated consultations, without an action plan 
communicated to the patient, featured more strongly in the 
interviews with patients in England and Denmark than in 
Sweden.
Patients may welcome reassurance from their PCP about 
their suspicious symptoms, and this may not be a problem 
if the practitioner takes responsibility for following up the 
patient as part of safety netting—the process of commu-
nicating with patient what to expect, documenting any 
action plans and following the patient up as agreed.46 A 
Swedish lung cancer patient explained that the GP had 
telephoned to see ‘how she was’ after a gastroscopy and 
made an urgent referral:
Sweden—LC123: I got a referral to ultrasound 
of my thyroid and upper gastro. And then they 
discovered in a gastroscopy that I had oesophagitis 
… [a week later the GP] called to ask how I was. I 
said, “now it is bad,” I said. “I think I have to go to 
the hospital urgently as it is now, it’s … I cannot 
breathe.” “Come here”, she said, “and we'll make an 
urgent referral”.
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Our international qualitative comparison has considered 
four potentially modifiable features of the prediagnostic 
experience of lung and bowel cancer patients. Across 
the countries, there are many similarities in how symp-
toms were experienced and in awareness of what the 
symptoms might mean. Our analysis suggests differences 
between countries in people’s accounts of their willing-
ness to consult and reconsult, their descriptions of what 
happened during consultations and for those who did not 
receive an immediate referral, their confusion or clarity 
about what they should look for, when to return and what 
to expect. Reluctance and practical barriers to consulting 
the GP, and uncertainty about whether and when to reat-
tend after an initial consultation, appeared more evident 
in interviews in Denmark and England. This indicates 
the benefit of communication of clear action plans to 
patients, including information on symptom develop-
ment and other safety netting approaches,47 which could 
well be developed more. PCPs action plans might include 
a ‘test of time’, yet this reasoning should be clearly 
communicated to the patient. This could also mean that 
patients would receive more timely referrals and avoid 
the repeated visits to primary care which featured partic-
ularly in English and Danish interviews.31
strengths and weaknesses of the study
The study design—a cross-cultural comparison using 
in-depth qualitative interview—is the first of its kind to 
study the route to cancer diagnosis. Our findings suggest 
potentially modifiable factors that could improve timely 
diagnosis of cancer in all three countries, although the 
scope for improvement may be greater in England and 
Denmark.
This qualitative study was designed to illuminate find-
ings from the ICBP studies and is intended to be indica-
tive rather than conclusive. Findings extend observations 
from other research that highlights the centrality of the 
primary care encounter in prediagnostic experiences. 
Participants’ cancer disease stage is likely to have affected 
their experiences. To achieve diversity, we recruited 
people who were diagnosed with very early stage and 
others diagnosed with advanced disease in all three coun-
tries. Participants who were recruited via social media in 
Denmark and England may also be thought to have had 
different experiences than those recruited via clinics. All 
participants were, or had been, under specialist cancer 
care and within 6 months of diagnosis. Each data set was 
analysed by the country specific team, thus benefiting 
from familiarity with healthcare context, language and 
culture. These country-specific analyses were shared as 
part of a careful collaborative process, involving work-
shops, teleconferences and several drafts and further 
targeted analyses. Along with the teleconferences, these 
meetings helped to mitigate any potential for differences 
in the data arising from differences in country or disci-
plinary approaches to interviewing or analysis.41
strengths and weaknesses in relation to other studies
This study was designed to explore whether a cross-
country comparison of qualitative interviews could help 
to illuminate findings from the ICBP survival analyses 
and surveys. While the high-level comparisons of large 
quantitative databases and surveys provide invaluable 
information, qualitative studies can suggest why these 
patterns may occur and identify avenues for service rede-
sign, such as action plans, some of which could be imple-
mented without further research. We did not observe the 
consultations described by the patients and it is possible 
that the PCPs involved did try to communicate an action 
plan, even if it did not feature in the patient’s account. 
Again, we have no reason to suspect that variations in 
recall would differ between the countries. It is well known 
that public knowledge of cancer symptoms is insufficient 
to prompt people to seek help, as recently demonstrated 
in ICBP surveys.1 Our work was guided by insights from 
the social and healthcare sciences into the complexity 
inherent in decisions to consult. These are influenced 
by people’s ideas about their own candidacy, related 
to family history and health behaviours, as well as their 
access to care.25 28 48 Evans et al have shown that patients, 
and their doctors, may be falsely reassured if a symptom 
comes and goes, reasoning that intermittent symptoms 
are unlikely to be serious.24 Renzi and colleagues have 
drawn attention to the potential negative consequences 
of reassurance through an ‘all-clear’ result from investi-
gations, which could be given with or without an encour-
agement to return.45
This study provides further insight into ICBP findings 
of how cancer symptoms are managed in primary care, 
in particular, how delays may be compounded when 
a patient is not referred promptly and no clear plan is 
communicated about the circumstances in which they 
should return for further consultation or investiga-
tions.2 49 Current research is exploring how and why 
planning, communicating action plans to patients and 
following up are operationalised as part of safety netting 
in English primary care and what approaches are accept-
able to both GPs and patients.46
Implications for clinicians and policy-makers
There are several important differences between these 
three countries, for example, in access to secondary care, 
in spending on health services and in the numbers of 
licensed practitioners. The health system in England has 
less money, fewer doctors and nurses and fewer hospital 
beds then Sweden or Denmark.34–36 These factors may 
yet prove critical in limiting improvements in cancer 
survival. Patients in Sweden consult their GP less often 
than patients in England or Denmark but for longer.36 
Shorter consultations may not be efficient—patients in 
England consult their GPs for nearly 1 hour per year, yet 
spread over five appointments while, on average, patients 
in Sweden visit primary care twice a year but for a mean 
of 20 min per appointment.
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Through our international comparison, we have been 
able to identify opportunities for pathway and service 
improvement that could promote earlier stage diagnosis. 
The perception of systemic barriers (eg, access to PCP 
appointments) may prevent patients seeking timely help, 
even in the presence of potentially alarming symptoms 
(eg, blood in stools or a cough that lasts for 3 weeks). 
While awareness of symptoms may be important, there 
is a limit to how much effect increasing public awareness 
could have in settings where access is limited and people 
are uncertain when to consult or reconsult.23 26
The importance of safety netting was emphasised in the 
2015 guidance for suspected cancer from the UK National 
Institute for Health and Care Excellence50 and a 2011 
Delphi study of British GPs and primary care researchers 
led to publication of suggestions for how to make safety 
netting more effective.46 In Denmark, direct access to 
investigation from general practice, with the aim to lower 
the GPs’ threshold for referring and lengthy ‘wait-and-see’ 
approaches,30 is being investigated along with a focus on 
safety netting. Our findings suggest that clearly communi-
cated action plans at the end of any primary care consul-
tation could be encouraged, without the need for further 
research. This would be likely to improve the patient’s expe-
rience and may also reduce demand for repeated appoint-
ments and diagnostic delay.
unanswered questions/need for further research
Research is needed into ways of redesigning primary care 
services in all three countries to reduce (perceived) barriers 
to consultation. The National Institute for Health and Care 
Excellence has recommended that British PCPs employ 
safety netting to reduce delays in the diagnosis of cancer, 
but there has been little research to understand what consti-
tutes best practice. Further research might address how a 
‘test of time’ or ‘wait-and-see’ approach that includes clear 
planning affects the number of follow-up visits and cancer 
stage at diagnosis. We do not know how action planning 
is communicated in the consultation nor what effect this 
may have on the length or frequency of consultations. 
This could be explored in future mixed-methods research, 
ideally including conversation analysis of the consultation. 
Cross-country differences in referral and follow-up practices 
in patients with lung and bowel cancer could be investigated 
further, especially in the light of recent studies suggesting 
that smokers (in Denmark and England) may be less likely 
to consult. Is the same pattern apparent in Sweden—and if 
not, why not?
COnClusIOn
If all primary care consultations concluded with a clear 
description of what should happen next and the circum-
stances in which the patient should return, this might avert 
some of the uncertainty and repeated consultations that 
were described in these interviews. We conclude that there 
is an opportunity for clearer communication and better 
follow-up strategies in primary care—neither of which will 
put additional pressure on specialist services, yet hold the 
potential to reduce diagnostic delays with few additional 
resources.
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